Since others have previously also documented successful HDR gene editing strategies to repair or compensate defects in FANCA, FANCC, FANCD1/BRCA2 and FANCI, the combined data support that gene editing can be a promising therapeutic strategy to prevent onset of bone marrow failure in FA patients27,30,32,33. This evidence concerns the gene FANCI and Friedreich ataxia.